Genomic instability in cancer

Genomic instability is often associated with cancer and can be indicative of a poor prognosis for some types of cancer. But, is genomic instability a consequence of tumour progression or an active process that drives tumour evolution? The answer to this question has still not been entirely resolved. Many new findings have highlighted certain DNA repair pathways and cell cycle control processes that have important consequences for genomic stability and tumour cell biology. Indeed, there are numerous efforts to manipulate the DNA damage responses to selectively induce tumour cell death through catastrophic genomic instability, and some are already showing promise. Of course, radiotherapy and other existing chemotherapeutic agents should not be overlooked as therapeutic strategies by which DNA damage induces tumour cell death and there are various efforts to improve the response to radiotherapy and to understand responses (and resistance) to current cytotoxic chemotherapeutics. This series takes a look at the progress made in this field and the questions that remain about the role of genomic instability in cancer.


July 2013 Vol 13 No 7

End–joining, translocations and cancer

Samuel F. Bunting & Andre Nussenzweig


March 2013 Vol 13 No 3

In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Jonathan D. Moore



December 2012 Vol 12 No 12

DNA repair dysregulation from cancer driver to therapeutic target

Nicola J. Curtin


October 2012 Vol 12 No 10

Chromothripsis and cancer: causes and consequences of chromosome shattering

Josep V. Forment, Abderrahmane Kaidi & Stephen P. Jackson


October 2012 Vol 12 No 10

Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer

Gabriele Sulli, Raffaella Di Micco & Fabrizio d'Adda di Fagagna


September 2012 Vol 12 No 9

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Peter Bouwman & Jos Jonkers


March 2012 Vol 12 No 3

RB: mitotic implications of a tumour suppressor

Amity L. Manning and Nicholas J. Dyson


February 2012 Vol 12 No 2

Balancing repair and tolerance of DNA damage caused by alkylating agents

Dragony Fu, Jennifer A. Calvo & Leona D. Samson


January 2012 Vol 12 No 1

BRCA1 and BRCA2: different roles in a common pathway of genome protection

Rohini Roy, Jarin Chun & Simon N. Powell



July 2011 Vol 11 No 7

DNA interstrand crosslink repair and cancer

Andrew J. Deans & Stephen C. West


June 2011 Vol 11 No 6

Human cancers express mutator phenotypes: origin, consequences and targeting

Lawrence A. Loeb


April 2011 Vol 11 No 4

Strategies to improve radiotherapy with targeted drugs

Adrian C. Begg, Fiona A. Stewart & Conchita Vens


March 2011 Vol 11 No 3

Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins

Paula Martínez & María A. Blasco


March 2011 Vol 11 No 3

Transcriptional mutagenesis: causes and involvement in tumour development

Damien Brégeon & Paul W. Doetsch


February 2011 Vol 11 No 2

DNA polymerases and cancer

Sabine S. Lange, Kei-ichi Takata & Richard D. Wood



December 2010 Vol 10 No 12

Shared and separate functions of polo–like kinases and aurora kinases in cancer

Susanne M. A. Lens, Emile E. Voest & René H. Medema